Silvia Taylor - Novavax Insider

NVV1 Stock  EUR 8.31  0.26  3.03%   

Insider

Silvia Taylor is Senior Vice President of Investor Relations and Corporate Affairs of Novavax since 2020.
Tenure 4 years
Phone240 268 2000
Webhttps://www.novavax.com

Novavax Management Efficiency

The company has return on total asset (ROA) of (0.317) % which means that it has lost $0.317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.982) %, meaning that it generated substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities.
Novavax has accumulated 323.46 M in total debt with debt to equity ratio (D/E) of 8.24, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novavax has a current ratio of 1.02, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Novavax until it has trouble settling it off, either with new capital or with free cash flow. So, Novavax's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novavax sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novavax to invest in growth at high rates of return. When we think about Novavax's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

MBA MBASuperior Plus Corp
70
Eivind KallevikNorsk Hydro ASA
56
Marcello DamianiModerna
49
Rick CarronSuperior Plus Corp
N/A
Sean MarettBioNTech SE
58
Hilde AasheimNorsk Hydro ASA
65
Robert GreenSIVERS SEMICONDUCTORS AB
60
Ray JordanModerna
N/A
Tomas DuffySIVERS SEMICONDUCTORS AB
62
Sylke MaasBioNTech SE
N/A
Michael BoehlerBioNTech SE
N/A
John ReyndersModerna
N/A
Tracey FranklinModerna
39
Jens HolsteinBioNTech SE
60
Patric ErlandssonSIVERS SEMICONDUCTORS AB
51
Melissa MooreModerna
N/A
Juan AndresModerna
58
John ThuestadNorsk Hydro ASA
63
Therese HolmNorsk Hydro ASA
N/A
Israel RuizModerna
47
William IIReliance Steel Aluminum
55
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. NOVAVAX INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1541 people. Novavax (NVV1) is traded on Frankfurt Exchange in Germany and employs 1,541 people.

Management Performance

Novavax Leadership Team

Elected by the shareholders, the Novavax's board of directors comprises two types of representatives: Novavax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novavax. The board's role is to monitor Novavax's management team and ensure that shareholders' interests are well served. Novavax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novavax's outside directors are responsible for providing unbiased perspectives on the board's policies.
MBA BS, Exec Officer
Jody Lichaa, Senior Vice President - Quality Assurance
Stanley Erck, President, Chief Executive Officer, Director
Ben Machielse, Executive Vice President - CMC
Michael McManus, Independent Director
Brian Webb, Senior Vice President - Manufacturing
Rick Crowley, Chief Operating Officer, Executive Vice President
John Herrmann, Executive Vice President Chief Legal Officer
Filip Dubovsky, Senior Vice President Chief Medical Officer
Rachel King, Independent Director
Gary Evans, Independent Director
Margaret McGlynn, Independent Director
Jill Hoyt, Chief Human Resource Officer, Executive Vice President
Erika Trahan, Associate PR
Henrietta Ukwu, Senior Vice President Chief Regulatory and Quality Officer
Frank Czworka, Senior Vice President - Global Sales
Gregg Alton, Director
James CFA, CFO VP
Rajiv Modi, Director
John Trizzino, Executive Vice President, Chief Business Officer, Chief Financial Officer and Treasurer
JD Esq, VP Officer
Brian Rosen, Senior Vice President - Commercial Strategy
Richard Crowley, Ex COO
Gregory Covino, Chief Financial Officer, Executive Vice President
Silvia Taylor, Senior Vice President of Investor Relations and Corporate Affairs
John III, Chief VP
Biegie Lee, VP Officer
Gale Smith, VP Scientist
James Young, Independent Chairman of the Board
Gregory Glenn, President Research and Development
David Mott, Independent Director
Madelyn Caltabiano, Senior Vice President - Global Program Management
Richard Douglas, Independent Director

Novavax Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novavax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Novavax Stock

When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Novavax Stock please use our How to Invest in Novavax guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.